Q2 2024 EPS Estimates for USANA Health Sciences, Inc. (NYSE:USNA) Cut by Sidoti Csr

USANA Health Sciences, Inc. (NYSE:USNA) – Equities research analysts at Sidoti Csr lowered their Q2 2024 earnings per share (EPS) estimates for shares of USANA Health Sciences in a research note issued to investors on Wednesday, May 1st. Sidoti Csr analyst A. Lebiedzinski now anticipates that the company will post earnings of $0.62 per share for the quarter, down from their previous forecast of $0.67. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.73 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q3 2024 earnings at $0.64 EPS, Q4 2024 earnings at $0.68 EPS, FY2024 earnings at $2.80 EPS, Q1 2025 earnings at $0.86 EPS, Q2 2025 earnings at $0.79 EPS, Q3 2025 earnings at $0.86 EPS and Q4 2025 earnings at $0.88 EPS.

Several other research analysts have also recently issued reports on the stock. StockNews.com upgraded shares of USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Friday, January 12th. DA Davidson decreased their price target on USANA Health Sciences from $53.00 to $48.00 and set a “neutral” rating for the company in a research note on Thursday, February 22nd.

USANA Health Sciences Trading Up 3.4 %

USANA Health Sciences stock opened at $47.10 on Thursday. USANA Health Sciences has a 52 week low of $41.45 and a 52 week high of $69.60. The stock has a market cap of $906.20 million, a price-to-earnings ratio of 14.67, a PEG ratio of 1.27 and a beta of 0.94. The company’s 50-day moving average price is $46.69 and its two-hundred day moving average price is $48.43.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.35. The business had revenue of $221.08 million for the quarter, compared to analysts’ expectations of $206.70 million. USANA Health Sciences had a net margin of 6.88% and a return on equity of 12.94%.

Institutional Trading of USANA Health Sciences

Several large investors have recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new position in USANA Health Sciences during the fourth quarter valued at $66,000. CWM LLC increased its holdings in shares of USANA Health Sciences by 49.6% in the 4th quarter. CWM LLC now owns 1,267 shares of the company’s stock valued at $68,000 after purchasing an additional 420 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of USANA Health Sciences by 60.6% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,376 shares of the company’s stock worth $198,000 after purchasing an additional 1,274 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of USANA Health Sciences during the fourth quarter worth approximately $266,000. Finally, Teacher Retirement System of Texas acquired a new stake in shares of USANA Health Sciences during the third quarter worth approximately $297,000. 54.25% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Daniel A. Macuga sold 3,791 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $47.14, for a total value of $178,707.74. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, insider Daniel A. Macuga sold 3,791 shares of the business’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $47.14, for a total transaction of $178,707.74. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Robert A. Sinnott sold 3,945 shares of the stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $46.55, for a total value of $183,639.75. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,598 shares of company stock worth $1,379,499. 0.33% of the stock is owned by corporate insiders.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.